Healthcare & Pharmaceuticals
Johnson & Johnson has been fined $1.2 billion in Arkansas over the sales of Risperdal, an antipsychotic drug. A circuit judge ruled that the company did not warn patients that the drug places elderly patients with dementia at an increased risk of major weight gain, possible diabetes and potential death.
CrocTail is an extension of the Crocodyl.org Wiki web site project, an online compendium profiling the accountability and transparency track records of multinational corporations. Developed with support from the Sunlight Foundation, CrocTail users can search the entire subsidiaries database. In this new version, users can click on different years and see how subsidiary relationships for a company have changed over time.
JOHANNESBURG, South Africa About 100 picketers demonstrated Monday outside the offices of the Pfizer drug company, saying its offer of free treatment for an AIDS-related brain infection was insufficient.
Early in March, Bausch & Lomb received a troubling phone call from a New Jersey eye doctor. Dr. David S. Chu, a specialist in cornea diseases, alerted the company that three of his recent patients had been afflicted with a microbe that caused a potentially blinding eye infection.
Merck's lobbying campaign for mandatory vaccination of school girls provided funding for a prominent women's non-profit. The ensuing uproar has created a backlash against the pharmaceutical giant.
Actavis, the world's third-largest generic drug manufacturer, has been sued by New York state to prevent it from forcing patients to take a new version of a popular Alzheimer's drug. The company is attempting to hook patients on an extended release version before its U.S. patent expires next year.
A Congressional investigation of the money that drug companies give as supposed educational grants has found that the payments are growing rapidly and are sometimes steered by marketing executives to doctors and groups who push unapproved uses of drugs.
Over the last two years, thousands of people have gathered to counter the annual conventions of the biotechnology industry in Boston and San Diego. This year, people will be converging on Toronto to broaden the biojustice movement and challenge the biotechnology industry and their vision for our future. It will be a gathering to learn, strategize and network about genetic engineering in agriculture and pharmaceuticals, biowarfare, genetic and non-genetic discrimination, trade regimes and corporate control, patenting of life and more. This event is timed to challenge the industry's annual convention BIO2002, Toronto, June 9-12.